
Let’s deliver life-changing therapies together - OXB
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, …
OXB Sweatproof Jewelry | Designed for Active Life
OXB pieces are built for everyday wear — through every workout, shower, and moment that matters. Wear it 24/7 through every run, class, and shower. Crafted in gold-filled, solid gold, …
OXB, OXB:LSE profile - FT.com - Financial Times
Dec 24, 2025 · OXB (OXB:LSE) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.
Oxford Biomedica - Wikipedia
Oxford Biomedica (OXB) is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange and is a constituent of the …
Oxford BioMedica plc (OXB) Stock Price & News - Google Finance
Get the latest Oxford BioMedica plc (OXB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
OXB Sweatproof Jewelry (@shopoxb) • Instagram photos and videos
40K Followers, 1,946 Following, 1,338 Posts - OXB Sweatproof Jewelry (@shopoxb) on Instagram: "💧sweatproof + waterproof jewelry 🏆women’s health best fitness jewelry"
Oxford Biomedica rebrands as OXB reinforcing transformation
Sep 18, 2024 · OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its …
OXB - LinkedIn
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life...
One of the original pioneers in gene and cell therapy - oxb.com
OXB is one of the original pioneers in gene and cell therapy. We’re already collaborating with some of the world’s most innovative pharmaceutical and biotechnology companies towards a …
News - OXB
Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has acquired the remaining 10% …